Mycotopia Therapies, Inc. (AIBT) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
480 22ND STREET HEYBURN, ID 83336 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2833 - Medicinal Chemicals and Botanical Products (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 185 | 279 | 386 | 1,268 | 57 | 709 | |||
| Cash and cash equivalent | 185 | 279 | 386 | 1,268 | 57 | 709 | |||
| Receivables | 1 | ||||||||
| Prepaid expense | 8 | ||||||||
| Disposal group, including discontinued operation | 35 | 947 | |||||||
| Other current assets | 48 | 50 | |||||||
| Other undisclosed current assets | 315 | (500) | |||||||
| Total current assets: | 185 | 279 | 386 | 1,268 | 455 | 1,215 | |||
| Noncurrent Assets | |||||||||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | (728) | 0 | 1 | 2 | 1 | ||||
| Intangible asset, including goodwill, after accumulated amortization, including: | 1,272 | 1,940 | |||||||
| Intangible asset, excluding goodwill, after accumulated amortization | |||||||||
| Other undisclosed intangible asset, including goodwill, after accumulated amortization | 1,272 | 1,940 | |||||||
| Other undisclosed noncurrent assets | 728 | ||||||||
| Total noncurrent assets: | 1,272 | 1,940 | 1 | 2 | 1 | ||||
| TOTAL ASSETS: | 1,457 | 2,219 | 387 | 1,270 | 455 | 1,215 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 283 | 341 | 336 | 171 | 1 | 56 | |||
| Accrued liabilities | 400 | 240 | 10 | 1 | 56 | ||||
| Other undisclosed accounts payable and accrued liabilities | (116) | 102 | 336 | 161 | |||||
| Debt | 1,100 | 1,091 | 141 | ||||||
| Other liabilities | 507 | ||||||||
| Due to related parties | ✕ | ✕ | ✕ | 125 | |||||
| Other undisclosed current liabilities | 3,468 | 2,816 | 288 | 10 | |||||
| Total current liabilities: | 4,852 | 4,248 | 765 | 306 | 1 | 563 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 514 | ||||||||
| Long-term debt, excluding current maturities | 514 | ||||||||
| Liabilities, other than long-term debt | 500 | ||||||||
| Due to related parties | ✕ | ✕ | ✕ | 500 | |||||
| Other undisclosed noncurrent liabilities | 124 | ||||||||
| Total noncurrent liabilities: | 514 | 624 | |||||||
| Total liabilities: | 4,852 | 4,248 | 1,279 | 930 | 1 | 563 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (3,395) | (2,028) | (891) | 340 | 454 | 652 | |||
| Common stock | 40 | 15 | 15 | 14 | 13 | 12 | |||
| Additional paid in capital | 7,374 | 6,918 | 6,873 | 3,176 | 70 | 26 | |||
| Retained earnings (accumulated deficit) | (10,809) | (8,961) | (7,780) | (2,850) | 371 | 613 | |||
| Other undisclosed equity, attributable to parent | 0 | ||||||||
| Total equity: | (3,395) | (2,028) | (891) | 340 | 454 | 652 | |||
| TOTAL LIABILITIES AND EQUITY: | 1,457 | 2,219 | 387 | 1,270 | 455 | 1,215 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Other undisclosed Revenues) | ||||||||
| Gross profit: | ||||||||
| Operating expenses | (1,635) | (617) | (1,736) | (2,669) | (252) | |||
| Operating loss: | (1,635) | (617) | (1,736) | (2,669) | (252) | |||
| Nonoperating expense | (213) | (565) | (876) | (152) | (2) | |||
| Investment income, nonoperating | 16 | |||||||
| Other nonoperating income | 22 | |||||||
| Interest and debt expense | (565) | (868) | (143) | (0) | ||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | ||||||||
| Loss from continuing operations before equity method investments, income taxes: | (1,848) | (1,746) | (3,480) | (2,964) | (253) | |||
| Other undisclosed income (loss) from continuing operations before income taxes | 565 | 868 | 143 | 0 | ||||
| Loss from continuing operations: | (1,848) | (1,181) | (2,612) | (2,821) | (253) | |||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (2,821) | 85 | (253) | |
| Income from discontinued operations | 85 | |||||||
| Other undisclosed net income (loss) | (327) | 258 | ||||||
| Net income (loss) available to common stockholders, diluted: | (1,848) | (1,181) | (2,612) | (2,821) | (242) | 5 | ||
Comprehensive Income ($ in thousands)
| 9/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (1,848) | (1,181) | (2,612) | (2,821) | (242) | 5 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (1,848) | (1,181) | (2,612) | (2,821) | (242) | 5 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.